BOVIE MEDICAL HIRES DIRECTOR OF MARKETING AND TWO NEW REGION MANAGERS
CLEARWATER, FL – March 4, 2016 – Bovie Medical, a maker of medical devices and supplies, and the developer of J-Plasma®, a patented new surgical product, today announced the hire of a Director of Marketing and two new Region Managers for its J-Plasma® product line.
Bovie’s new Director of Marketing, Jeffrey Hoffman, is an experienced medical device executive with significant marketing and sales expertise, as well as specialized knowledge in advanced energy technology, including plasma.
Prior to joining Bovie, Mr. Hoffman was Director of Global Marketing and Product Management at Plasma Surgical and held several executive positions during his 13-year tenure at CryoLife/ CryoLife Europa where he oversaw global strategy development, marketing and product management for specialized product lines.
Commenting on this appointment, Robert L. Gershon, Chief Executive Officer noted, “We are pleased to have Jeff on board and expect him to play an important role in increasing and broadening nationwide adoption of J-Plasma® as well as supporting product launches and other revenue-generating activities within our Core business.”
In addition, the Company has hired two Region Managers, Robert Timerman and Dennis Keast, to help advance the adoption of J-Plasma® and oversee the product’s expanding geographic sales footprint. Mr. Timerman will be responsible for the Eastern U.S. while Mr. Keast will oversee the Central U.S.
Mr. Timerman has extensive medical device sales experience, having held senior positions at companies including CryoLife, BrainLAB, Biomet Orthopedics and Smith & Nephew.
Prior to joining Bovie, Mr. Keast was Regional Sales Director at Cardiva Medical, and has held senior sales and business development roles at companies including Covidien, KCI, Nova Biomedical and Sakura Finetek USA.
“Robert and Dennis will be charged with accelerating J-Plasma® sales in their respective regions, building upon the progress we have already made in gaining surgeon adoption and hospital VAC approvals. In addition, we continue to build a highly-credentialed direct sales force to drive accelerated product sales in 2016 and beyond, Mr. Gershon said.
Messieurs Hoffman, Timerman and Keast will each receive an inducement grant of 20,000 shares of Bovie Medical stock with a four (4) year vesting period. The option strike prices will equal the closing price of Bovie shares as of the close of trade today.
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com.
MBS Value Partners